These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38327681)

  • 1. Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma.
    Goldlust SA; Nabors LB; Hsu S; Mohile N; Duic PJ; Benkers T; Singer S; Rao M; Cappello L; Silberman SL; Farmer G
    Neurooncol Adv; 2024; 6(1):vdae009. PubMed ID: 38327681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
    Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent efficacy of bevacizumab in recurrent glioblastoma.
    Melhem JM; Tahir A; Calabrese E; Granovskaya I; Atenafu EG; Sahgal A; Lim-Fat MJ; Perry JR
    J Neurooncol; 2023 Feb; 161(3):633-641. PubMed ID: 36749445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
    Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
    J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
    Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
    J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors.
    Varghese AM; Cardin DB; Hersch J; Benson AB; Hochster HS; Makris L; Hamada K; Berlin JD; Saltz LB
    Clin Cancer Res; 2020 Apr; 26(7):1555-1562. PubMed ID: 31924737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map.
    Fu M; Zhou Z; Huang X; Chen Z; Zhang L; Zhang J; Hua W; Mao Y
    BMC Cancer; 2023 Jun; 23(1):544. PubMed ID: 37316802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
    Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
    Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
    Ghiaseddin A; Reardon D; Massey W; Mannerino A; Lipp ES; Herndon JE; McSherry F; Desjardins A; Randazzo D; Friedman HS; Peters KB
    Oncologist; 2018 Feb; 23(2):157-e21. PubMed ID: 29133513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
    Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
    J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Trial of Radiosurgery Dose Escalation Plus Bevacizumab in Patients With Recurrent/Progressive Glioblastoma.
    Abbassy M; Missios S; Barnett GH; Brewer C; Peereboom DM; Ahluwalia M; Neyman G; Chao ST; Suh JH; Vogelbaum MA
    Neurosurgery; 2018 Sep; 83(3):385-392. PubMed ID: 28973311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
    Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
    Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
    McBain C; Lawrie TA; Rogozińska E; Kernohan A; Robinson T; Jefferies S
    Cochrane Database Syst Rev; 2021 May; 5(1):CD013579. PubMed ID: 34559423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study.
    Lu G; Rao M; Zhu P; Liang B; El-Nazer RT; Fonkem E; Bhattacharjee MB; Zhu JJ
    Front Neurol; 2019; 10():42. PubMed ID: 30766509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology.
    Ranjan S; Skorupan N; Ye X; Sivakumar A; Yankulina O; Kamson D; Grossman SA; Dzaye O; Holdhoff M
    Neurooncol Pract; 2020 Jan; 7(1):52-58. PubMed ID: 32257284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
    Lu G; Zhu P; Rao M; Linendoll N; Buja LM; Bhattacharjee MB; Brown RE; Ballester LY; Tian X; Pilichowska M; Wu JK; Hergenroeder GW; Glass WF; Chen L; Zhang R; Pillai AK; Hunter RL; Zhu JJ
    J Neurooncol; 2022 Oct; 160(1):221-231. PubMed ID: 36203027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance).
    Galanis E; Anderson SK; Twohy E; Butowski NA; Hormigo A; Schiff D; Omuro A; Jaeckle KA; Kumar S; Kaufmann TJ; Geyer S; Kumthekar PU; Campian J; Giannini C; Buckner JC; Wen PY
    Neurooncol Adv; 2022; 4(1):vdac041. PubMed ID: 35664553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial.
    Zhao S; Zhang M; Zhang Q; Wu J; Dai H
    BMC Cancer; 2024 Jan; 24(1):6. PubMed ID: 38166698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).
    Cloughesy TF; Brenner A; de Groot JF; Butowski NA; Zach L; Campian JL; Ellingson BM; Freedman LS; Cohen YC; Lowenton-Spier N; Rachmilewitz Minei T; Fain Shmueli S; ; Wen PY
    Neuro Oncol; 2020 May; 22(5):705-717. PubMed ID: 31844890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.